Safety and efficacy of 125 I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation
To evaluate the safety and efficacy of I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation. We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2019-07, Vol.145 (7), p.1907 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 1907 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 145 |
| creator | Xiang, Zhanwang Bai, Mingjun Li, Guohong Zou, Bihui Zhong, Zhihui Gao, Fei Wu, Chun Huang, Mingsheng Zhang, Fujun |
| description | To evaluate the safety and efficacy of
I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation.
We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3-6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided
I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B).
The median survival time was 19 months (range of 3-36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P |
| doi_str_mv | 10.1007/s00432-019-02943-x |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_31161374</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31161374</sourcerecordid><originalsourceid>FETCH-pubmed_primary_311613743</originalsourceid><addsrcrecordid>eNqFTstKxDAUDYLMjI8fcCH3B6pJ01pmLYqudT_cZm6mkTQpNymYtT9uBF27Og_OORwhbpS8U1IO90nKTreNVPtGtvtON59nYqd-LKV1vxUXKX1IqYZ-aDdiq5V6UHroduLrDS3lAhiOQNY6g6ZAtKDaHl5hZDRTyRMxLgVsZBidx1ylB7-GEzCZlZmCoQSW4wwTLZijIe9XjwwG2bgQZwS0tVbziUx2MUDdwrFuVX4lzi36RNe_eClun5_eH1-aZR1nOh4WdjNyOfy91v8GvgGlClT2</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and efficacy of 125 I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Xiang, Zhanwang ; Bai, Mingjun ; Li, Guohong ; Zou, Bihui ; Zhong, Zhihui ; Gao, Fei ; Wu, Chun ; Huang, Mingsheng ; Zhang, Fujun</creator><creatorcontrib>Xiang, Zhanwang ; Bai, Mingjun ; Li, Guohong ; Zou, Bihui ; Zhong, Zhihui ; Gao, Fei ; Wu, Chun ; Huang, Mingsheng ; Zhang, Fujun</creatorcontrib><description>To evaluate the safety and efficacy of
I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation.
We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3-6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided
I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B).
The median survival time was 19 months (range of 3-36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred.
CT-guided
I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.</description><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-019-02943-x</identifier><identifier>PMID: 31161374</identifier><language>eng</language><publisher>Germany</publisher><subject>Brachytherapy - adverse effects ; Brachytherapy - methods ; Carcinoma, Hepatocellular - radiotherapy ; Carcinoma, Hepatocellular - surgery ; Female ; Humans ; Iodine Radioisotopes - administration & dosage ; Liver Neoplasms - radiotherapy ; Liver Neoplasms - surgery ; Male ; Middle Aged ; Retrospective Studies</subject><ispartof>Journal of cancer research and clinical oncology, 2019-07, Vol.145 (7), p.1907</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-7978-5992</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31161374$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiang, Zhanwang</creatorcontrib><creatorcontrib>Bai, Mingjun</creatorcontrib><creatorcontrib>Li, Guohong</creatorcontrib><creatorcontrib>Zou, Bihui</creatorcontrib><creatorcontrib>Zhong, Zhihui</creatorcontrib><creatorcontrib>Gao, Fei</creatorcontrib><creatorcontrib>Wu, Chun</creatorcontrib><creatorcontrib>Huang, Mingsheng</creatorcontrib><creatorcontrib>Zhang, Fujun</creatorcontrib><title>Safety and efficacy of 125 I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><description>To evaluate the safety and efficacy of
I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation.
We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3-6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided
I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B).
The median survival time was 19 months (range of 3-36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred.
CT-guided
I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.</description><subject>Brachytherapy - adverse effects</subject><subject>Brachytherapy - methods</subject><subject>Carcinoma, Hepatocellular - radiotherapy</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Iodine Radioisotopes - administration & dosage</subject><subject>Liver Neoplasms - radiotherapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFTstKxDAUDYLMjI8fcCH3B6pJ01pmLYqudT_cZm6mkTQpNymYtT9uBF27Og_OORwhbpS8U1IO90nKTreNVPtGtvtON59nYqd-LKV1vxUXKX1IqYZ-aDdiq5V6UHroduLrDS3lAhiOQNY6g6ZAtKDaHl5hZDRTyRMxLgVsZBidx1ylB7-GEzCZlZmCoQSW4wwTLZijIe9XjwwG2bgQZwS0tVbziUx2MUDdwrFuVX4lzi36RNe_eClun5_eH1-aZR1nOh4WdjNyOfy91v8GvgGlClT2</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Xiang, Zhanwang</creator><creator>Bai, Mingjun</creator><creator>Li, Guohong</creator><creator>Zou, Bihui</creator><creator>Zhong, Zhihui</creator><creator>Gao, Fei</creator><creator>Wu, Chun</creator><creator>Huang, Mingsheng</creator><creator>Zhang, Fujun</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><orcidid>https://orcid.org/0000-0002-7978-5992</orcidid></search><sort><creationdate>201907</creationdate><title>Safety and efficacy of 125 I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation</title><author>Xiang, Zhanwang ; Bai, Mingjun ; Li, Guohong ; Zou, Bihui ; Zhong, Zhihui ; Gao, Fei ; Wu, Chun ; Huang, Mingsheng ; Zhang, Fujun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_311613743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Brachytherapy - adverse effects</topic><topic>Brachytherapy - methods</topic><topic>Carcinoma, Hepatocellular - radiotherapy</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Iodine Radioisotopes - administration & dosage</topic><topic>Liver Neoplasms - radiotherapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiang, Zhanwang</creatorcontrib><creatorcontrib>Bai, Mingjun</creatorcontrib><creatorcontrib>Li, Guohong</creatorcontrib><creatorcontrib>Zou, Bihui</creatorcontrib><creatorcontrib>Zhong, Zhihui</creatorcontrib><creatorcontrib>Gao, Fei</creatorcontrib><creatorcontrib>Wu, Chun</creatorcontrib><creatorcontrib>Huang, Mingsheng</creatorcontrib><creatorcontrib>Zhang, Fujun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiang, Zhanwang</au><au>Bai, Mingjun</au><au>Li, Guohong</au><au>Zou, Bihui</au><au>Zhong, Zhihui</au><au>Gao, Fei</au><au>Wu, Chun</au><au>Huang, Mingsheng</au><au>Zhang, Fujun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of 125 I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2019-07</date><risdate>2019</risdate><volume>145</volume><issue>7</issue><spage>1907</spage><pages>1907-</pages><eissn>1432-1335</eissn><abstract>To evaluate the safety and efficacy of
I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation.
We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3-6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided
I brachytherapy (group A), and 51 patients were treated with supportive and symptomatic treatments (group B).
The median survival time was 19 months (range of 3-36 months). The local response rate (LRR) at 3, 6, 12, 18, 24, 30 and 36 months in group A was 81.8%, 65.9%, 59.1%, 45.0%, 38.6%, 22.7%, 11.4%, respectively, and 64.7%, 47.1%, 33.3%, 25.4%, 15.7%, 11.7%, 7.8%, respectively, in group B (P < 0.05). The mean progression-free survival time (PFST) and overall survival (OS) of group A were significantly longer than those of group B. Alpha fetoprotein (AFP) and tumor size were independent factors that affected the PFST and OS, normal AFP levels and less than 1-cm tumor diameter had better PFST and OS (P < 0.05). No massive bleeding or serious complications occurred.
CT-guided
I brachytherapy is safe and effective for the treatment of bilateral lung recurrences from HCC after resection or ablation.</abstract><cop>Germany</cop><pmid>31161374</pmid><doi>10.1007/s00432-019-02943-x</doi><orcidid>https://orcid.org/0000-0002-7978-5992</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1432-1335 |
| ispartof | Journal of cancer research and clinical oncology, 2019-07, Vol.145 (7), p.1907 |
| issn | 1432-1335 |
| language | eng |
| recordid | cdi_pubmed_primary_31161374 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Brachytherapy - adverse effects Brachytherapy - methods Carcinoma, Hepatocellular - radiotherapy Carcinoma, Hepatocellular - surgery Female Humans Iodine Radioisotopes - administration & dosage Liver Neoplasms - radiotherapy Liver Neoplasms - surgery Male Middle Aged Retrospective Studies |
| title | Safety and efficacy of 125 I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T00%3A31%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20125%20I%20brachytherapy%20for%20bilateral%20lung%20recurrences%20from%20hepatocellular%20carcinoma%20after%20resection%20or%20ablation&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Xiang,%20Zhanwang&rft.date=2019-07&rft.volume=145&rft.issue=7&rft.spage=1907&rft.pages=1907-&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-019-02943-x&rft_dat=%3Cpubmed%3E31161374%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31161374&rfr_iscdi=true |